Clinical Trials

Common cold

In the year 1999 a study was able to show in patients with a viral respiratory tract infection (ie common cold) that by therapy with Esberitox®N, the complaints were alleviated much faster than under placebo. The duration of the illness was shortened by two days.

 


 


Source:
H.H. Henneicke-von Zepelin et al.: Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre study. Curr Medical Research and Opinion Vol.15 (3), 214-227 (1999)

Use with antibiotic

In the year 2002 a study was done on patients requiring antibiotic because of severe bacterial infection (acute exacerbation of chronic bronchitis). The study shows that recovery is much faster for patients taking Esberitox®N with antibiotic rather than antibiotic by itself. Recovery is seven days faster.

 




 

 


Source:
Gert Kohler et al.: Esberitox®N as Supportive Therapy when Providing Standard Antibiotic Treatment in Subjects with a Severe Bacterial Infection (Acute Exacerbation of Chronic Bronchitis). Chemotherapy 48,259-266 (2002)

-------------------------------

 
 
 
Clinical trials efficacy
Faster recovery from cold
Concomitant treatment with antibiotic
Use of Esberitox®N in children
 
 
CLINICAL STUDIES
Clinical trials conducted with Esberitox®N
 
   
 
Acute and Chronic Respiratory tract infections (of viral or bacterial origin)
 
Wüstenberg P, Henneicke-von Zepelin HH, Köhler G, Stammwitz U. Adv Ther 1999;16:
51–70.
Efficacy and mode of action of an immunomodulator herbal preparation
containing echinacea, wild indigo and white cedar.
 
Henneicke-von Zepelin HH, Hentschel C, Schnitker J, Kohnen R,
Köhler G, Wüstenberg P.
Curr Med Res Opin 1999;15:214–27. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory
tract infection): results of a randomised, double blind, placebo controlled,
multicentre study.

PDF 3.2MB
Naser B, Lund B, Heinneicke-von Zepelin HH, Köhler G, Lehmacher W,
Scaglione F.
Phytomedicine 2005; in press. A randomised double-blind placebo-controlled clinical dose–response trial of an extract of Baptisia/Echinacea and Thuja in the
treatment of patients with common cold.

PDF 1.7MB
HD Reitz. Notabene medici (1990) 362-366. Immunomodulators with phytotherapeutic agents.  
MD Vorberg Arztliche Praxis 36 (1984) 97-98. For colds, stimulate the nonspecific immune system  
   
 
Accompanying an antibiotics therapy in case of severe bacterial infection
 
von Blumröder WO. Z Allgemeinmed 1985;61:271–3. Angina lacunaris.  
Hauke W, Köhler G, Henneicke-von Zepelin HH, Freudenstein J. Chemotherapy 2002;48:259–66. Esberitox®N as Supportive therapy when providing standard antibiotic
treatment in subjects with a severe bacterial infection (acute exacerbation
of chronic bronchitis).

PDF 0.4MB
M.Zimmer. Therapiewoche (35) (1985), 36: 4024-4028 Specific conservative treatment of acute sinusitis in the ENT practice.  
H.Stolze et al. Der Kassenarzt 23 (1983) 43-38 A treatment with antibiotics can be optimized by additional immunostimulation. (Acute Tonsilitis)  
   
 
Leukopenias after radiation or cytostatic treatment
 
R. Bendel et al. Onkologie 12 (3) 1989, 32-38 Adjuvant therapy with Esberitox®N in patients receiving chemo- and radiation therapy for advanced breast cancer.
   
 
Herpes simplex labialis
 
H. Bockhorst Z allerg. Med. 58 (1982) 1795-1798 The treatment of herpes simplex in practice.
   
 
Treatment in children
 
Kohler et al. Zeitschrift fur Phytotherapie 19 (1998), 318-322 Children’s dosage of phytopharmaceuticals: Representative, Exemplary, Age stratified Dosage practice for Esberitox®N the Herbal combination of active substances.
K.D. Blunck. Kinderartzt 14 (1983), 8:991-992 Susceptibility to infection at children’s home – to increase the resistance against infections.
   
 

A clinically proven standardized extract phytomedicine used to stop common colds from progressing and prevent complications.